A newly developed glucagon sandwich ELISA is useful for more accurate glucagon evaluation than the currently used sandwich ELISA in subjects with elevated plasma proglucagon‐derived peptide levels
Aims/Introduction Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by sandwich enzyme‐linked immunosorbent assay (ELISA), but the currently used sandwich ELISA cross‐reacts with proglucagon‐derived pe...
Saved in:
Published in | Journal of diabetes investigation Vol. 14; no. 5; pp. 648 - 658 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Japan
John Wiley & Sons, Inc
01.05.2023
John Wiley and Sons Inc Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aims/Introduction
Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by sandwich enzyme‐linked immunosorbent assay (ELISA), but the currently used sandwich ELISA cross‐reacts with proglucagon‐derived peptides, thereby providing incorrect results in subjects with elevated plasma proglucagon‐derived peptide levels. We aimed to develop a more broadly reliable ELISA for measuring plasma glucagon levels.
Materials and Methods
A new sandwich ELISA was developed using newly generated monoclonal antibodies against glucagon. After its validation, plasma glucagon levels were measured with the new ELISA and the currently used ELISA in subjects who underwent laparoscopic sleeve gastrectomy (LSG) and in outpatients with suspected glucose intolerance. The ELISA results were compared with those from liquid chromatography‐high resolution mass (LC‐HRMS) analysis, which we previously established as the most accurate measuring system.
Results
The new ELISA has high specificity (<1% cross‐reactivities) and high sensitivity (a lower range of 0.31 pmol/L). Plasma glucagon values in the subjects who underwent laparoscopic sleeve gastrectomy and some outpatients with suspected glucose intolerance differed between the new ELISA and the currently used ELISA. These subjects also showed markedly high plasma glicentin levels. Despite the elevated plasma glicentin levels, the new ELISA showed better positive correlation with LC‐HRMS than did the currently used ELISA.
Conclusions
The new ELISA enables more accurate measurement of plasma glucagon than the currently used ELISA, even in subjects with elevated proglucagon‐derived peptide levels. It should be clinically useful in elucidating the pathophysiology of individual diabetic patients.
A new glucagon sandwich enzyme‐linked immunosorbent assay (ELISA) has been developed that enables highly reliable measurement. The new ELISA provided much more reliable glucagon values than the currently used ELISA even in the subjects with elevated plasma proglucagon‐derived peptide levels. This new ELISA should be clinically useful in elucidating the pathophysiology of individual diabetic patients. |
---|---|
AbstractList | Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by sandwich enzyme-linked immunosorbent assay (ELISA), but the currently used sandwich ELISA cross-reacts with proglucagon-derived peptides, thereby providing incorrect results in subjects with elevated plasma proglucagon-derived peptide levels. We aimed to develop a more broadly reliable ELISA for measuring plasma glucagon levels.AIMS/INTRODUCTIONGlucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by sandwich enzyme-linked immunosorbent assay (ELISA), but the currently used sandwich ELISA cross-reacts with proglucagon-derived peptides, thereby providing incorrect results in subjects with elevated plasma proglucagon-derived peptide levels. We aimed to develop a more broadly reliable ELISA for measuring plasma glucagon levels.A new sandwich ELISA was developed using newly generated monoclonal antibodies against glucagon. After its validation, plasma glucagon levels were measured with the new ELISA and the currently used ELISA in subjects who underwent laparoscopic sleeve gastrectomy (LSG) and in outpatients with suspected glucose intolerance. The ELISA results were compared with those from liquid chromatography-high resolution mass (LC-HRMS) analysis, which we previously established as the most accurate measuring system.MATERIALS AND METHODSA new sandwich ELISA was developed using newly generated monoclonal antibodies against glucagon. After its validation, plasma glucagon levels were measured with the new ELISA and the currently used ELISA in subjects who underwent laparoscopic sleeve gastrectomy (LSG) and in outpatients with suspected glucose intolerance. The ELISA results were compared with those from liquid chromatography-high resolution mass (LC-HRMS) analysis, which we previously established as the most accurate measuring system.The new ELISA has high specificity (<1% cross-reactivities) and high sensitivity (a lower range of 0.31 pmol/L). Plasma glucagon values in the subjects who underwent laparoscopic sleeve gastrectomy and some outpatients with suspected glucose intolerance differed between the new ELISA and the currently used ELISA. These subjects also showed markedly high plasma glicentin levels. Despite the elevated plasma glicentin levels, the new ELISA showed better positive correlation with LC-HRMS than did the currently used ELISA.RESULTSThe new ELISA has high specificity (<1% cross-reactivities) and high sensitivity (a lower range of 0.31 pmol/L). Plasma glucagon values in the subjects who underwent laparoscopic sleeve gastrectomy and some outpatients with suspected glucose intolerance differed between the new ELISA and the currently used ELISA. These subjects also showed markedly high plasma glicentin levels. Despite the elevated plasma glicentin levels, the new ELISA showed better positive correlation with LC-HRMS than did the currently used ELISA.The new ELISA enables more accurate measurement of plasma glucagon than the currently used ELISA, even in subjects with elevated proglucagon-derived peptide levels. It should be clinically useful in elucidating the pathophysiology of individual diabetic patients.CONCLUSIONSThe new ELISA enables more accurate measurement of plasma glucagon than the currently used ELISA, even in subjects with elevated proglucagon-derived peptide levels. It should be clinically useful in elucidating the pathophysiology of individual diabetic patients. A new glucagon sandwich enzyme‐linked immunosorbent assay (ELISA) has been developed that enables highly reliable measurement. The new ELISA provided much more reliable glucagon values than the currently used ELISA even in the subjects with elevated plasma proglucagon‐derived peptide levels. This new ELISA should be clinically useful in elucidating the pathophysiology of individual diabetic patients. Abstract Aims/Introduction Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by sandwich enzyme‐linked immunosorbent assay (ELISA), but the currently used sandwich ELISA cross‐reacts with proglucagon‐derived peptides, thereby providing incorrect results in subjects with elevated plasma proglucagon‐derived peptide levels. We aimed to develop a more broadly reliable ELISA for measuring plasma glucagon levels. Materials and Methods A new sandwich ELISA was developed using newly generated monoclonal antibodies against glucagon. After its validation, plasma glucagon levels were measured with the new ELISA and the currently used ELISA in subjects who underwent laparoscopic sleeve gastrectomy (LSG) and in outpatients with suspected glucose intolerance. The ELISA results were compared with those from liquid chromatography‐high resolution mass (LC‐HRMS) analysis, which we previously established as the most accurate measuring system. Results The new ELISA has high specificity (<1% cross‐reactivities) and high sensitivity (a lower range of 0.31 pmol/L). Plasma glucagon values in the subjects who underwent laparoscopic sleeve gastrectomy and some outpatients with suspected glucose intolerance differed between the new ELISA and the currently used ELISA. These subjects also showed markedly high plasma glicentin levels. Despite the elevated plasma glicentin levels, the new ELISA showed better positive correlation with LC‐HRMS than did the currently used ELISA. Conclusions The new ELISA enables more accurate measurement of plasma glucagon than the currently used ELISA, even in subjects with elevated proglucagon‐derived peptide levels. It should be clinically useful in elucidating the pathophysiology of individual diabetic patients. Aims/Introduction Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by sandwich enzyme‐linked immunosorbent assay (ELISA), but the currently used sandwich ELISA cross‐reacts with proglucagon‐derived peptides, thereby providing incorrect results in subjects with elevated plasma proglucagon‐derived peptide levels. We aimed to develop a more broadly reliable ELISA for measuring plasma glucagon levels. Materials and Methods A new sandwich ELISA was developed using newly generated monoclonal antibodies against glucagon. After its validation, plasma glucagon levels were measured with the new ELISA and the currently used ELISA in subjects who underwent laparoscopic sleeve gastrectomy (LSG) and in outpatients with suspected glucose intolerance. The ELISA results were compared with those from liquid chromatography‐high resolution mass (LC‐HRMS) analysis, which we previously established as the most accurate measuring system. Results The new ELISA has high specificity (<1% cross‐reactivities) and high sensitivity (a lower range of 0.31 pmol/L). Plasma glucagon values in the subjects who underwent laparoscopic sleeve gastrectomy and some outpatients with suspected glucose intolerance differed between the new ELISA and the currently used ELISA. These subjects also showed markedly high plasma glicentin levels. Despite the elevated plasma glicentin levels, the new ELISA showed better positive correlation with LC‐HRMS than did the currently used ELISA. Conclusions The new ELISA enables more accurate measurement of plasma glucagon than the currently used ELISA, even in subjects with elevated proglucagon‐derived peptide levels. It should be clinically useful in elucidating the pathophysiology of individual diabetic patients. A new glucagon sandwich enzyme‐linked immunosorbent assay (ELISA) has been developed that enables highly reliable measurement. The new ELISA provided much more reliable glucagon values than the currently used ELISA even in the subjects with elevated plasma proglucagon‐derived peptide levels. This new ELISA should be clinically useful in elucidating the pathophysiology of individual diabetic patients. Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by sandwich enzyme-linked immunosorbent assay (ELISA), but the currently used sandwich ELISA cross-reacts with proglucagon-derived peptides, thereby providing incorrect results in subjects with elevated plasma proglucagon-derived peptide levels. We aimed to develop a more broadly reliable ELISA for measuring plasma glucagon levels. A new sandwich ELISA was developed using newly generated monoclonal antibodies against glucagon. After its validation, plasma glucagon levels were measured with the new ELISA and the currently used ELISA in subjects who underwent laparoscopic sleeve gastrectomy (LSG) and in outpatients with suspected glucose intolerance. The ELISA results were compared with those from liquid chromatography-high resolution mass (LC-HRMS) analysis, which we previously established as the most accurate measuring system. The new ELISA has high specificity (<1% cross-reactivities) and high sensitivity (a lower range of 0.31 pmol/L). Plasma glucagon values in the subjects who underwent laparoscopic sleeve gastrectomy and some outpatients with suspected glucose intolerance differed between the new ELISA and the currently used ELISA. These subjects also showed markedly high plasma glicentin levels. Despite the elevated plasma glicentin levels, the new ELISA showed better positive correlation with LC-HRMS than did the currently used ELISA. The new ELISA enables more accurate measurement of plasma glucagon than the currently used ELISA, even in subjects with elevated proglucagon-derived peptide levels. It should be clinically useful in elucidating the pathophysiology of individual diabetic patients. Aims/IntroductionGlucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by sandwich enzyme-linked immunosorbent assay (ELISA), but the currently used sandwich ELISA cross-reacts with proglucagon-derived peptides, thereby providing incorrect results in subjects with elevated plasma proglucagon-derived peptide levels. We aimed to develop a more broadly reliable ELISA for measuring plasma glucagon levels.Materials and MethodsA new sandwich ELISA was developed using newly generated monoclonal antibodies against glucagon. After its validation, plasma glucagon levels were measured with the new ELISA and the currently used ELISA in subjects who underwent laparoscopic sleeve gastrectomy (LSG) and in outpatients with suspected glucose intolerance. The ELISA results were compared with those from liquid chromatography-high resolution mass (LC-HRMS) analysis, which we previously established as the most accurate measuring system.ResultsThe new ELISA has high specificity (<1% cross-reactivities) and high sensitivity (a lower range of 0.31 pmol/L). Plasma glucagon values in the subjects who underwent laparoscopic sleeve gastrectomy and some outpatients with suspected glucose intolerance differed between the new ELISA and the currently used ELISA. These subjects also showed markedly high plasma glicentin levels. Despite the elevated plasma glicentin levels, the new ELISA showed better positive correlation with LC-HRMS than did the currently used ELISA.ConclusionsThe new ELISA enables more accurate measurement of plasma glucagon than the currently used ELISA, even in subjects with elevated proglucagon-derived peptide levels. It should be clinically useful in elucidating the pathophysiology of individual diabetic patients. |
Author | Yoshida, Morikatsu Maruyama, Nobuhiro Ida, Takanori Kobayashi, Masaki Hayashi, Yoshitaka Yamamoto, Yukako Kitada, Masahisa Miyazato, Mikiya Togawa, Takeshi Kitamura, Tadahiro Kashiwagi, Atsunori |
AuthorAffiliation | 3 Department of Diabetes and Endocrinology Omi Medical Center Shiga Japan 2 Immuno‐Biological Laboratories Co., Ltd Gunma Japan 5 Division for Identification and Analysis of Bioactive Peptides, Department of Bioactive Peptides, Frontier Science Research Center University of Miyazaki Miyazaki Japan 1 Metabolic Signal Research Center, Institute for Molecular and Cellular Regulation Gunma University Gunma Japan 7 Kitada Internal Medicine Clinic Gifu Japan 6 Department of Biochemistry National Cerebral and Cardiovascular Center Research Institute Osaka Japan 8 Division of Stress Adaptation and Protection, Department of Endocrinology, Research Institute of Environmental Medicine Nagoya University Nagoya Japan 4 Department of Bariatric and Metabolic Surgery Omi Medical Center Shiga Japan |
AuthorAffiliation_xml | – name: 3 Department of Diabetes and Endocrinology Omi Medical Center Shiga Japan – name: 2 Immuno‐Biological Laboratories Co., Ltd Gunma Japan – name: 5 Division for Identification and Analysis of Bioactive Peptides, Department of Bioactive Peptides, Frontier Science Research Center University of Miyazaki Miyazaki Japan – name: 8 Division of Stress Adaptation and Protection, Department of Endocrinology, Research Institute of Environmental Medicine Nagoya University Nagoya Japan – name: 1 Metabolic Signal Research Center, Institute for Molecular and Cellular Regulation Gunma University Gunma Japan – name: 4 Department of Bariatric and Metabolic Surgery Omi Medical Center Shiga Japan – name: 6 Department of Biochemistry National Cerebral and Cardiovascular Center Research Institute Osaka Japan – name: 7 Kitada Internal Medicine Clinic Gifu Japan |
Author_xml | – sequence: 1 givenname: Masaki surname: Kobayashi fullname: Kobayashi, Masaki organization: Gunma University – sequence: 2 givenname: Nobuhiro surname: Maruyama fullname: Maruyama, Nobuhiro organization: Immuno‐Biological Laboratories Co., Ltd – sequence: 3 givenname: Yukako surname: Yamamoto fullname: Yamamoto, Yukako organization: Omi Medical Center – sequence: 4 givenname: Takeshi surname: Togawa fullname: Togawa, Takeshi organization: Omi Medical Center – sequence: 5 givenname: Takanori surname: Ida fullname: Ida, Takanori organization: University of Miyazaki – sequence: 6 givenname: Morikatsu surname: Yoshida fullname: Yoshida, Morikatsu organization: National Cerebral and Cardiovascular Center Research Institute – sequence: 7 givenname: Mikiya surname: Miyazato fullname: Miyazato, Mikiya organization: National Cerebral and Cardiovascular Center Research Institute – sequence: 8 givenname: Masahisa surname: Kitada fullname: Kitada, Masahisa organization: Kitada Internal Medicine Clinic – sequence: 9 givenname: Yoshitaka orcidid: 0000-0002-7557-4303 surname: Hayashi fullname: Hayashi, Yoshitaka organization: Nagoya University – sequence: 10 givenname: Atsunori orcidid: 0000-0002-6049-3236 surname: Kashiwagi fullname: Kashiwagi, Atsunori organization: Omi Medical Center – sequence: 11 givenname: Tadahiro orcidid: 0000-0001-8809-8740 surname: Kitamura fullname: Kitamura, Tadahiro email: kitamura@gunma-u.ac.jp organization: Gunma University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36729958$$D View this record in MEDLINE/PubMed |
BookMark | eNp1ks1u1DAUhSNUREvpghdAltiUxbSx48T2Co1KgUEjsQDWlse5nvHIEwc7mdHseASeigfhSXDmp9ACXjiWfc7n65vzNDtpfANZ9hznVziN62Vtr3AhePUoOyM5zUcYE3pyt8bVaXYR4zJPo-C8qtiT7LSoGBGi5GfZjzFqYOO2qIY1ON9Cjeau12ruGxRVU2-sXqDb6eTTGNmI-gimd8j4gFY-AFJa90F18NsDa-V61dm07BZqmAAlTYCmS5ckf_0XNl3Uz5agu4g2tlsgcAnSJWHrVFwp1AZ_xP_89r2GYNfDIbSdrQG5oe74LHtslItwcfieZ1_e3n6-eT-afnw3uRlPR7osaDUydDYzjFNMtcqJBoGLkqd2FURrACE0z6mCXJdY0KoShtZYFJoJDtzgiuPiPJvsubVXS9kGu1JhK72ycrfhw1yq0FntQMKMCVCcGFYYKkyteMk4yauSYJMbRhPr9Z7V9rMV1Dq1KCh3D3r_pLELOfdriXOMhcA8ES4PhOC_9hA7ubJRg3OqAd9HSRhLD6GMDdKXD6RL34cm9UoSnoJBuMBlUr34s6S7Wo55SYLrvUAHH2MAI7Xtdr87VWhdKk0OoZQplHIXyuR49cBxhP5Le6BvrIPt_4Xyw5vJ3vELLPr07Q |
CitedBy_id | crossref_primary_10_1111_jdi_14249 crossref_primary_10_1038_s41574_025_01100_4 crossref_primary_10_1016_j_foodchem_2023_137947 crossref_primary_10_3390_nu15183913 crossref_primary_10_1007_s13340_024_00704_x crossref_primary_10_2116_bunsekikagaku_72_233 crossref_primary_10_1210_clinem_dgae174 crossref_primary_10_1210_clinem_dgae460 |
Cites_doi | 10.1016/S0140-6736(18)30726-8 10.1111/dom.12672 10.1016/S0140-6736(75)92375-2 10.2337/dc15-1643 10.1111/jdi.13325 10.1155/2016/8352957 10.1111/jdi.12797 10.2337/db16-0994 10.1038/nm1168 10.1007/s00125-014-3283-z 10.1210/endo-119-4-1467 10.1016/j.ebiom.2016.03.034 10.1111/jdi.12400 10.1210/js.2018-00142 10.1507/endocrj.EJ20-0079 10.2337/db16-0240 10.1210/er.2018-00117 10.1007/s00216-017-0534-0 10.1016/j.celrep.2019.01.047 10.1172/JCI112846 10.1007/s13340-010-0011-x 10.1016/j.soard.2018.01.039 10.1507/endocrj.EJ18-0372 10.1111/jdi.13110 10.1111/j.1463-1326.2011.01452.x 10.1007/s00595-015-1134-2 10.1126/science.1089999 10.1080/00365513.2021.2016943 10.1210/me.2009-0296 |
ContentType | Journal Article |
Copyright | 2023 The Authors. published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. 2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. 2023. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2023 The Authors. published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. – notice: 2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. – notice: 2023. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7TM 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1111/jdi.13986 |
DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Nucleic Acids Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journal Collection |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts Immunology Abstracts ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Newly developed glucagon sandwich ELISA |
EISSN | 2040-1124 |
EndPage | 658 |
ExternalDocumentID | oai_doaj_org_article_eb79ea82f73f49fda8578206521f0f74 PMC10119918 36729958 10_1111_jdi_13986 JDI13986 |
Genre | article Journal Article |
GeographicLocations | United States--US Japan |
GeographicLocations_xml | – name: United States--US – name: Japan |
GroupedDBID | --- 05W 0R~ 1OC 24P 31~ 4.4 50Y 5DZ 5VS 7X7 8-0 8-1 8FI 8FJ AAHHS AANHP AAZKR ABDBF ABJNI ABUWG ACBWZ ACCFJ ACCMX ACGFO ACPRK ACRPL ACUHS ACXQS ACYXJ ADBBV ADKYN ADNMO ADPDF ADRAZ ADZMN AEEZP AEGXH AENEX AEQDE AFKRA AHMBA AIAGR AIWBW AJBDE ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS ASPBG AVUZU AVWKF AZFZN BAWUL BCNDV BDRZF BENPR BPHCQ BVXVI CAG CCPQU COF DIK EBD EBS EJD FYUFA GODZA GROUPED_DOAJ GX1 HMCUK HYE HZ~ KQ8 LH4 LW6 M48 MY. O9- OK1 OVD PIMPY PQQKQ PROAC RPM RX1 SUPJJ TEORI UKHRP WIN AAYXX AGQPQ CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 3V. 7T5 7TM 7XB 8FK AAMMB AEFGJ AGXDD AIDQK AIDYY AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c5346-f4bbf78414ca02ce9135812432ccee99c804ae0c5194669f4d193c798e8f16813 |
IEDL.DBID | 7X7 |
ISSN | 2040-1116 2040-1124 |
IngestDate | Wed Aug 27 01:31:44 EDT 2025 Thu Aug 21 18:38:27 EDT 2025 Fri Jul 11 09:51:32 EDT 2025 Mon Jul 14 09:55:25 EDT 2025 Wed Feb 19 02:24:10 EST 2025 Tue Jul 01 02:48:50 EDT 2025 Thu Apr 24 23:04:16 EDT 2025 Wed Jan 22 16:24:02 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Glucagon Sandwich ELISA Glicentin |
Language | English |
License | Attribution-NonCommercial-NoDerivs 2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5346-f4bbf78414ca02ce9135812432ccee99c804ae0c5194669f4d193c798e8f16813 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0001-8809-8740 0000-0002-6049-3236 0000-0002-7557-4303 |
OpenAccessLink | https://www.proquest.com/docview/2803828915?pq-origsite=%requestingapplication% |
PMID | 36729958 |
PQID | 2803828915 |
PQPubID | 1006415 |
PageCount | 658 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_eb79ea82f73f49fda8578206521f0f74 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10119918 proquest_miscellaneous_2771944778 proquest_journals_2803828915 pubmed_primary_36729958 crossref_citationtrail_10_1111_jdi_13986 crossref_primary_10_1111_jdi_13986 wiley_primary_10_1111_jdi_13986_JDI13986 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | May 2023 |
PublicationDateYYYYMMDD | 2023-05-01 |
PublicationDate_xml | – month: 05 year: 2023 text: May 2023 |
PublicationDecade | 2020 |
PublicationPlace | Japan |
PublicationPlace_xml | – name: Japan – name: Richmond – name: Hoboken |
PublicationTitle | Journal of diabetes investigation |
PublicationTitleAlternate | J Diabetes Investig |
PublicationYear | 2023 |
Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
References | 1987; 79 2009; 23 1986; 119 2019; 3 2019; 10 2017; 66 2011; 13 2016; 2016 2016; 18 2016; 39 2018; 9 2018; 39 2016; 7 2018; 391 2017; 409 2021; 12 2010; 1 2022; 82 2019; 66 2019; 26 2016; 65 1975; 1 2014; 57 2020; 67 1975; 187 2005; 11 2016; 46 2018; 14 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_14_1 e_1_2_7_13_1 e_1_2_7_12_1 e_1_2_7_11_1 e_1_2_7_10_1 e_1_2_7_26_1 e_1_2_7_27_1 e_1_2_7_28_1 e_1_2_7_29_1 e_1_2_7_30_1 e_1_2_7_25_1 e_1_2_7_24_1 e_1_2_7_23_1 e_1_2_7_22_1 e_1_2_7_21_1 e_1_2_7_20_1 |
References_xml | – volume: 57 start-page: 1919 year: 2014 end-page: 1926 article-title: Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? publication-title: Diabetologia – volume: 46 start-page: 268 year: 2016 end-page: 274 article-title: Potential mechanisms mediating improved glycemic control after bariatric/metabolic surgery publication-title: Surg Today – volume: 1 start-page: 14 year: 1975 end-page: 16 article-title: The essential role of glucagon in the pathogenesis of diabetes mellitus publication-title: Lancet – volume: 391 start-page: 2607 year: 2018 end-page: 2618 article-title: MEDI0382, a GLP‐1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double‐blind, ascending dose and phase 2a study publication-title: Lancet – volume: 409 start-page: 5911 year: 2017 end-page: 5918 article-title: Accurate analytical method for human plasma glucagon levels using liquid chromatography‐high resolution mass spectrometry: comparison with commercially available immunoassays publication-title: Anal Bioanal Chem – volume: 187 start-page: 544 year: 1975 end-page: 547 article-title: Glucagon: Role in the hyperglycemia of diabetes mellitus publication-title: Science – volume: 82 start-page: 75 year: 2022 end-page: 83 article-title: On measurements of glucagon secretion in healthy, obese, and roux‐en‐Y gastric bypass operated individuals using sandwich ELISA publication-title: Scand J Clin Lab Invest – volume: 18 start-page: 795 year: 2016 end-page: 802 article-title: Effects of multiple ascending doses of the glucagon receptor antagonist PF‐06291874 in patients with type 2 diabetes mellitus publication-title: Diabetes Obes Metab – volume: 23 start-page: 1990 year: 2009 end-page: 1999 article-title: Mice deficient for glucagon gene‐derived peptides display normoglycemia and hyperplasia of islet {alpha}‐cells but not of intestinal L‐cells publication-title: Mol Endocrinol – volume: 3 start-page: 42 year: 2019 end-page: 51 article-title: Postprandial plasma glucagon kinetics in type 2 diabetes mellitus: comparison of immunoassay and mass spectrometry publication-title: J Endocr Soc – volume: 1 start-page: 99 year: 2010 end-page: 103 article-title: Laparoscopic sleeve gastrectomy leads to rapid improvement of glucose tolerance and insulin secretion with enhanced glucagon‐like peptide (GLP‐1) secretion publication-title: Diabetol Int – volume: 14 start-page: 562 year: 2018 end-page: 568 article-title: Gastrectomy with roux‐en‐Y reconstruction as a lean model of bariatric surgery publication-title: Surg Obes Relat Dis – volume: 13 start-page: 89 issue: Suppl 1 year: 2011 end-page: 94 article-title: Regulation of glucagon secretion by incretins publication-title: Diabetes Obes Metab – volume: 67 start-page: 903 year: 2020 end-page: 922 article-title: Plasma glucagon levels measured by sandwich ELISA are correlated with impaired glucose tolerance in type 2 diabetes publication-title: Endocr J – volume: 12 start-page: 286 year: 2021 end-page: 289 article-title: Pseudo‐hyperglucagonemia was observed in pancreatectomized patients when measured by glucagon sandwich enzyme‐linked immunosorbent assay publication-title: J Diabetes Investig – volume: 39 start-page: 1241 year: 2016 end-page: 1249 article-title: Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12‐ and 24‐week phase 2 studies publication-title: Diabetes Care – volume: 65 start-page: 3473 year: 2016 end-page: 3481 article-title: Insulin resistance is accompanied by increased fasting glucagon and delayed glucagon suppression in individuals with normal and impaired glucose regulation publication-title: Diabetes – volume: 119 start-page: 1467 year: 1986 end-page: 1475 article-title: Glucagon‐like peptides GLP‐1 and GLP‐2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas* publication-title: Endocrinology – volume: 11 start-page: 90 year: 2005 end-page: 94 article-title: Free fatty acids regulate gut incretin glucagon‐like peptide‐1 secretion through GPR120 publication-title: Nat Med – volume: 39 start-page: 719 year: 2018 end-page: 738 article-title: Targeting the incretin/glucagon system with triagonists to treat diabetes publication-title: Endocr Rev – volume: 2016 year: 2016 article-title: Inability of some commercial assays to measure suppression of glucagon secretion publication-title: J Diabetes Res – volume: 79 start-page: 547 year: 1987 end-page: 556 article-title: Hyperglucagonemia and insulin‐mediated glucose metabolism publication-title: J Clin Invest – volume: 66 start-page: 235 year: 2017 end-page: 240 article-title: Glucagon and amino acids are linked in a mutual feedback cycle: the liver‐α‐cell axis publication-title: Diabetes – volume: 10 start-page: 1391 year: 2019 end-page: 1393 article-title: Glutaminostatin: Another facet of glucagon as a regulator of plasma amino acid concentrations publication-title: J Diabetes Investig – volume: 7 start-page: 324 year: 2016 end-page: 331 article-title: Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme‐linked immunosorbent assay publication-title: J Diabetes Investig – volume: 9 start-page: 464 year: 2018 end-page: 472 article-title: Regulation of amino acid metabolism and alpha‐cell proliferation by glucagon publication-title: J Diabetes Investig – volume: 66 start-page: 663 year: 2019 end-page: 675 article-title: Basal glucagon hypersecretion and response to oral glucose load in prediabetes and mild type 2 diabetes publication-title: Endocr J – volume: 26 start-page: 1399 year: 2019 end-page: 408.e6 article-title: Important role of the GLP‐1 Axis for glucose homeostasis after bariatric surgery publication-title: Cell Rep – volume: 7 start-page: 112 year: 2016 end-page: 120 article-title: Oxyntomodulin identified as a marker of type 2 diabetes and gastric bypass surgery by mass‐spectrometry based profiling of human plasma publication-title: EBioMedicine – ident: e_1_2_7_11_1 doi: 10.1016/S0140-6736(18)30726-8 – ident: e_1_2_7_6_1 doi: 10.1111/dom.12672 – ident: e_1_2_7_3_1 doi: 10.1016/S0140-6736(75)92375-2 – ident: e_1_2_7_5_1 doi: 10.2337/dc15-1643 – ident: e_1_2_7_19_1 doi: 10.1111/jdi.13325 – ident: e_1_2_7_27_1 doi: 10.1155/2016/8352957 – ident: e_1_2_7_8_1 doi: 10.1111/jdi.12797 – ident: e_1_2_7_7_1 doi: 10.2337/db16-0994 – ident: e_1_2_7_30_1 doi: 10.1038/nm1168 – ident: e_1_2_7_13_1 doi: 10.1007/s00125-014-3283-z – ident: e_1_2_7_28_1 doi: 10.1210/endo-119-4-1467 – ident: e_1_2_7_29_1 doi: 10.1016/j.ebiom.2016.03.034 – ident: e_1_2_7_16_1 doi: 10.1111/jdi.12400 – ident: e_1_2_7_15_1 doi: 10.1210/js.2018-00142 – ident: e_1_2_7_26_1 doi: 10.1507/endocrj.EJ20-0079 – ident: e_1_2_7_24_1 doi: 10.2337/db16-0240 – ident: e_1_2_7_10_1 doi: 10.1210/er.2018-00117 – ident: e_1_2_7_14_1 doi: 10.1007/s00216-017-0534-0 – ident: e_1_2_7_20_1 doi: 10.1016/j.celrep.2019.01.047 – ident: e_1_2_7_4_1 doi: 10.1172/JCI112846 – ident: e_1_2_7_23_1 doi: 10.1007/s13340-010-0011-x – ident: e_1_2_7_18_1 doi: 10.1016/j.soard.2018.01.039 – ident: e_1_2_7_25_1 doi: 10.1507/endocrj.EJ18-0372 – ident: e_1_2_7_9_1 doi: 10.1111/jdi.13110 – ident: e_1_2_7_12_1 doi: 10.1111/j.1463-1326.2011.01452.x – ident: e_1_2_7_22_1 doi: 10.1007/s00595-015-1134-2 – ident: e_1_2_7_2_1 doi: 10.1126/science.1089999 – ident: e_1_2_7_17_1 doi: 10.1080/00365513.2021.2016943 – ident: e_1_2_7_21_1 doi: 10.1210/me.2009-0296 |
SSID | ssj0000388667 |
Score | 2.3499238 |
Snippet | Aims/Introduction
Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently... Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by... Aims/IntroductionGlucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently... A new glucagon sandwich enzyme‐linked immunosorbent assay (ELISA) has been developed that enables highly reliable measurement. The new ELISA provided much more... Abstract Aims/Introduction Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are... |
SourceID | doaj pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 648 |
SubjectTerms | Cloning Diabetes Diabetes Mellitus Enzyme-linked immunosorbent assay Enzyme-Linked Immunosorbent Assay - methods Gastrectomy Gastrointestinal surgery Glicentin Glucagon Glucose Glucose Intolerance - diagnosis Glucose tolerance Humans Intolerance Laparoscopy Liquid chromatography Monoclonal antibodies Obesity Original Pathophysiology Peptide Hormones Peptides Plasma Polypeptides Proglucagon Sandwich ELISA |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journal Collection dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtUwELVQF4gNojwvFGQQi24CceL4sbxAq7aibKBSd5GfNNIltyJNETs-ga_iQ_gSZpw0vVctYsMmiuJHHHucOWOPzxDy0uoQcstsppVTGfdgsKpch0wb7l0VQQGnGEuHH8TeET84ro5XQn2hT9hADzx03OtgpQ5GFVGWkevojUICdlCcBYt5lIkJFHTeijGV_sGlUiKFjy3QZQ4mtBhphZIbj29eAfLB89Mryihx9l8HNK_6S67i2KSIdu-Q2yOCpPOh5ZvkRmjvkpuH4x75PfJrTgEqL77T8TxU8BT90s3nZUs70_pvjTuhO-_3P85p09G-C7FfUICuFF1uqXGuR_aIyzKXfOAUl9nhEqgbWJ3gJVDeX6kWXtRbXODpKK7zUjzDDnV6egpY_Yuh6BQ2Vv_7x08Pk-AcE9HBxge6wHZ398nR7s6nt3vZGK0hc1XJRRa5tRF3MbkzeeGCZkitVvCycKCItXYq5ybkDiAjF0JH7gE7OqlVUJEJxcoHZKNdtuERocwUnrlc8WjBgBGlEdJpKC6dd7aUcUa2L4atdiOVOUbUWNSTSeObOo3wjLyYsp4O_B3XZXqDYz9lQMrt9AAEsR4Fsf6XIM7I1oXk1ON_oKsx9hfatKyakedTMsxg3JYxbVj2kEdK6BIupZqRh4OgTS0pBRg_uoIUtSaCa01dT2mbk8QSzpDNTzMoup2k9e-fXx-82083j_9HPzwhtwoAgoNT6BbZOPvah6cA3M7sszRH_wA2EEN2 priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LbxMxELZKkRAXxLuBggzi0MtW-_D6cUAoQKu2IlwgUm8rrx_tSmFTsl2g_48fxozjbIkauERR7PF61zOZb-zZbwh5Uyvn0jqrEyWNTJiFgFWmyiVKM2tKDw441FiafOZHU3ZyWp5ukVWNzfgAu42hHdaTmi5m-7--X70Dg387ZOXYZh-AjOS3yG1wSALtcxJRfvhDLqTkoZZsjvlzIMIjx9Ca9JpnCgT-m1DnzeTJv0Ft8EqH98m9CCfpeLn-D8iWax-SO5N4YP6I_B5TwM2zKxpfjnKWYpK6Ppu3tNOt_dmYc3rw6fjLmDYd7Tvn-xkFHEsx_5ZqY3qkkriWuSYHp7jnDh-OmiXFE1wE5O2NYeFCfY27PR3FTV-KL7TDmJZeAHD_pilmiMXhEwv28AObMNfGOjrDWXePyfTw4OuHoyQWbkhMWTCeeFbXHg80mdFpbpzKkGUtZ0VuwCcrZWTKtEsNoEfGufLMAow0QkknfcZlVjwh2-28dTuEZjq3mUkl8zXEMrzQXBgF4sJYUxfCj8jeatEqE1nNsbjGrBqiG9tUYX1H5PXQ9WJJ5bGp03tc-aEDsm-HH-aLsyoac-VqoZyWuReFZ8pbLbEoAIC5PPOpF2xEdld6U600usIyYBjeZuWIvBqawZjxhEa3bt5DHyHgkTAh5Ig8XarZMJOCQxykSmiRawq4NtX1lrY5D4ThGRL7qQxE94Ku_vv2q5OPx-HLs__fwnNyNwe0t8z83CXbl4vevQB0dlm_DLb3BwKJOw0 priority: 102 providerName: Scholars Portal – databaseName: Wiley Online Library Open Access dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZKkRAXxLuBggzi0EtQHo4f4rRAq7aiCAkq9Rb52UZaslXTgLjxE_hV_BB-CTNONu2qReKyitYex4k98Tfj8TeEvDLK-8zkJlXSypQ5MFhlpnyqNHO2CrAAxxxLBx_57iHbP6qO1sib5VmYgR9icrihZsTvNSq4Nt1lJXfNa4Avkt8gN_FoLRLnF-zT5GBBmhMeM8gWGDUHQnxkFoqRPEvplfUo0vZfhzWvhkxehrJxLdq5S-6MIJLOhlG_R9Z8e5_cOhi3yR-Q3zMKaHn-g45HoryjGJqujxct7XTrvjf2hG5_2Ps8o01H-86Hfk4BvVKMuqXa2h4JJC5kLijBKXra4cdTOxA7wU1A3l1pFm7UG_TxdBRdvRSPsUObjp4CXP-qKcaFjc3_-fnLgR58w0KMsXGezrHf3UNyuLP95d1uOiZsSG1VMp4GZkzAjUxmdVZYr3JkVytYWVhYi5WyMmPaZxZQI-NcBeYAPlqhpJch5zIvH5H1dtH6DUJzXbjcZpIFAzYMLzUXVoG4sM6aUoSEbC2HrbYjmzkm1ZjXk1XjmjqOcEJeTlVPBwqP6yq9xbGfKiDrdvxjcXZcj0pceyOU17IIogxMBaclJgMAEFfkIQuCJWRzOXPq8VPQ1Zj-C83avErIi6kYlBh3ZnTrFz3UEQJeCRNCJuTxMNGmnpQc7B9VQYlcmYIrXV0taZuTSBSeI6GfykF0K87Wfz9-vf9-L148-f-qT8ntAhDfEP25SdbPz3r_DBDauXkeNfEvnac7IQ priority: 102 providerName: Wiley-Blackwell |
Title | A newly developed glucagon sandwich ELISA is useful for more accurate glucagon evaluation than the currently used sandwich ELISA in subjects with elevated plasma proglucagon‐derived peptide levels |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjdi.13986 https://www.ncbi.nlm.nih.gov/pubmed/36729958 https://www.proquest.com/docview/2803828915 https://www.proquest.com/docview/2771944778 https://pubmed.ncbi.nlm.nih.gov/PMC10119918 https://doaj.org/article/eb79ea82f73f49fda8578206521f0f74 |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZoKyEuiDeBsjKIQy-BPLyxfUJb2Kqt2KoCKu0tcvxoIy3ZpWlA_D9-GDNeb7arFi5RFD_ixGP7m_H4G0LeVtLapEqrWAotYmZAYRWJtLFUzOihgwXYx1ianBSHZ-x4OpwGg1sb3CpXc6KfqM1co438PUZRQu0gHX5Y_IgxahTuroYQGltkB6nL0KWLT3lvY0Gmk8IHkc3QcQ6GdRHIhbwzj6nfAf7BU9TXliTP3H8b3LzpNXkdzfrl6OABuR9wJB0tO_4huWObR-TuJOyUPyZ_RhQA8-w3DaeirKHona7O5w1tVWN-1fqCjj8ffR3RuqVda103owBgKTreUqV1hxwS6zJrVnCKxna4WKqX3E7wEihvblQLL-oqNPO0FK29FE-yQ52GLgCxf1cUXcNC9bGBgfATk9DJxlg6w1a3T8jZwfjbx8M4RGyI9TBnRexYVTncyWRaJZm2MkV6tYzlmYbFWEotEqZsogE2sqKQjhnAj5pLYYVLC5HmT8l2M2_sc0JTlZlUJ4K5CpSYIlcF1xKKc210lXMXkb1Vp5U60JljVI1Z2as1pi59_0bkTZ91seTwuC3TPvZ8nwFpt_2D-eV5GUZxaSsurRKZ47lj0hklMBoAoLgsdYnjLCK7K7kpw1zQlmvJjcjrPhlGMW7NqMbOO8jDOfwSxrmIyLOlmPUtyQtQgEC4IyI2BHCjqZspTX3hmcJTZPSTKRTd87L6788vjz8d-ZsX__-El-ReBjBv6fK5S7avLjv7CmDZVTUgWxk7HfgROCA7--OT0y8Db-KA64SJv6EgPZY |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELZKKgEXxJtAAYNA6mXLPpy1fUAopamSNokQtFJvi9ePNlLYhG6Xqn-KX8EPY2Z3s2nUwq2XKIof682Mx9_Y428IeZdKa_00SD0ptPCYAYdV-NJ6UjGjOw4W4DLH0mgc9w_Z3lHnaI38XtyFwbDKhU0sDbWZadwj_4BZlNA7CDqf5j89zBqFp6uLFBqVWuzbi3Nw2fKPgx2Q7_sw3O0dfO57dVYBT3ciFnuOpanD0zamlR9qKwOkAAtZFGpYMKTUwmfK-hqgDYtj6ZgBjKO5FFa4IBZBBP3eIussAlemRda3e-MvX5tdHeRWicu0tSGG6oEhiWs6ozJ8yEy2AHHhve1Li2CZK-A6gHs1TvMyfi4XwN375F6NXGm3UrUHZM1mD8ntUX02_4j86VKA6NMLWt_DsoZiPLw6nmU0V5k5n-gT2hsOvnXpJKdFbl0xpQCZKYb6UqV1gawVyzZLHnKK2_vwYamu2KTgIdDeXOkWHlSkuLGUU9xfpnh3Hvo0dA4-wg9FMRit7t4zMPV-YRGG9RhLpzjq_DE5vBFpPiGtbJbZZ4QGKjSB9gVzKbhNcaRiriU059roNOKuTTYXQkt0TaCOeTymSeNImUlSyrdN3jZV5xVryHWVtlHyTQUk-i5_mJ0eJ7XdSGzKpVUidDxyTDqjBOYfANwYBs53nLXJxkJvktr65MlyrrTJm6YY7AYeBqnMzgqowzn8JYxz0SZPKzVrRhLF4HLJDpSIFQVcGepqSTY5KbnJA-QQlAE03Sx19d-vn-ztDMovz___Cq_Jnf7BaJgMB-P9F-RuCCCzCjjdIK2z08K-BFB4lr6qZyIl32968v8FkTh16w |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELZKkSouiDcpBQwCqZel-_Cu7QNCgTRq-hISVMpt8frRRgqbtNtQ9a9x5ocx491sGrVw6yVaxY99eGb8jT3-hpB3hbQ2LKIikEKLgBlwWEUobSAVMzp1MAH7HEsHh9nOEdsdpsMV8nt-FgbDKuc20RtqM9G4Rr6FWZTQO4jSLdeERXzt9T9NTwPMIIU7rfN0GrWI7NnLC3Dfqo-DHoz1-zjub3__shM0GQYCnSYsCxwrCoc7b0yrMNZWRkgHFrMk1jB5SKlFyJQNNcAclmXSMQN4R3MprHBRJqIE-r1D7vIkjVDH-JC36zvIspL5BLYxBu2BSckaYiMfSGRGHwB74QnuK9OhzxpwE9S9HrF5FUn7qbD_gNxvMCzt1kL3kKzY8hFZO2h26R-TP10KYH18SZsTWdZQjIxXx5OSVqo0FyN9Qrf3B9-6dFTRWWXhU1MAzxSDfqnSeob8FYs2C0Zyigv98GOprnml4CbQ3lzrFm40K3CJqaK40kzxFD30aegUvIWfimJYWtN9YEAJf2ERBvgYS8f41NUTcnQrY_mUrJaT0j4nNFKxiXQomCvAgcoSlXEtoTnXRhcJdx2yOR-0XDdU6pjRY5y3LpUZ5X58O-RtW3Va84fcVOkzjnxbASm__R-Ts-O8sSC5Lbi0SsSOJ45JZ5TATASAIOPIhY6zDtmYy03e2KEqX2hNh7xpi8GC4LaQKu1kBnU4h0_COBcd8qwWs_ZJkgycL5lCiVgSwKVHXS4pRyeepTxCNkEZQdNNL6v_fv18tzfwF-v_f4XXZA1UPt8fHO69IPdiQJt15OkGWT0_m9mXgA7Pi1deDSn5cdt6_xeueHi7 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+newly+developed+glucagon+sandwich+ELISA+is+useful+for+more+accurate+glucagon+evaluation+than+the+currently+used+sandwich+ELISA+in+subjects+with+elevated+plasma+proglucagon-derived+peptide+levels&rft.jtitle=Journal+of+diabetes+investigation&rft.au=Kobayashi%2C+Masaki&rft.au=Maruyama%2C+Nobuhiro&rft.au=Yamamoto%2C+Yukako&rft.au=Togawa%2C+Takeshi&rft.date=2023-05-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=2040-1116&rft.eissn=2040-1124&rft.volume=14&rft.issue=5&rft.spage=648&rft.epage=658&rft_id=info:doi/10.1111%2Fjdi.13986&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2040-1116&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2040-1116&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2040-1116&client=summon |